(a)
(b)
Figure 3: Effect of substance P receptor antagonist pretreatment on doxorubicin-induced, reactive oxygen species (ROS) production in cardiomyocytes and triple-negative breast cancer cells. Levels of ROS as determined by the DCFDA assay, in response to DOX in aprepitant pretreated versus untreated rat H9C2 cardiomyocytes (a) and MDA-MB 231 TNBC cells (b) (, ANOVA, , for both). Only statistical comparisons between DOX and DOX + AP are shown.